ENFIERA - 100MG

DEFINES :

Enfiera 100 mg is an anticancer medicine which prevents the growth and spread of cancer cells in the body. Enfiera 100 mg Injectionwill help to prevent the Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with another anticancer drug like methotrexate is used for Enfiera 100 mg rheumatoid arthritis symptoms in adult treatment. Enfiera 100 mg Injection with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.

INDICATIONS

Enfiera 100mg and hyaluronidase human injection are given alone or combination with other drugs to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC).

Enfiera 100mg injection combination with methotrexate (Otrexup, Rasuvo, Xatmep, others) is also indicated for the treatment rheumatoid arthritis symptoms in adults that have been already treated with a some type of regimen knowns as tumor necrosis factor (TNF) inhibitor. Enfiera 100mg is a type in a classification of drugs called monoclonal antibodies.

Enfiera 100mg is used to killing cancer cells to treat NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by inhibiting the activity of the immune system parts that can injury the joints, veins, and other blood vessels and cause organs (heart and lungs) damage.

PREGNANCY CATEGORY

Category C: In animal studies reproduction describes an adverse effect on the fetus. There is no adequate and well developed studies in humans, using in pregnant women benefits by warrant use of the drug.

 LACTATION

The drug excretion into human milk is unknown. Because the drug is a higher protein molecule and has no information is available.

Women should not breast feed during Enfiera 100mg treatment and till12 months following last dose.

DOSAGE :

Enfiera injection is usually used to administrate only via intravenous infusion not by IV push or bolus.

Before Each Infusion the Drug Is Premediate :

First infusion:

Starting treatment rate of 50 mg/hr. is administer, in not showing infusion toxicity, rate raised up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.

Successive infusion:

initial at rate of 100 mg/hr., in not showing infusion toxicity, rate raised up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.

While combination with CHOP chemotherapy the injection Enfiera has not been given. Hence Premedication with corticosteroids must be considered.

Low grade or follicular non-Hodgkin’s lymphoma:

The drug Dose is 375 mg/m2 as an IV infusion.

Once weeks for 4 or 8 doses administrated for Relapsed treatment

Once weekly for 4 doses administrated for Retreatment for relapsed.

Previously untreated:

administer on day 1 of each cycle of chemotherapy, up to 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Enfiera 100mg in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent.

Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non – progression (following CVP chemotherapy completion 6 – 8 cycles):

On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse Large B- cell NHL

Chronic Lymphocytic Leukemia :

Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.

Component of Zevalin for treatment of NHL:

The dose 250 mg/m2 of Enfiera injection within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-) Zevalin.

7–9 days before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin.

Rheumatoid Arthritis :

When combination of Enfiera injection with methotrexate is administrated.

Enfiera injection given as two doses of 100mg IV infusion 2 weeks separated.

When glucocorticoids administered as methylprednisolone 100mg IV

Subsequent course based on clinical evaluation must administer every 24 weeks, but not early than every 16 weeks.

Granulomatosis Polyangiitis And Microscopic Polyangiitis

Enfiera injection administer Dose of 375 mg/m2 IV infusion weekly once for 4 weeks.

When Glucocorticoids given with methylprednisolone by dose of 1000 mg IV/ day for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vacuities This drug should initiate within 14 days before or with the starting of Enfiera injection and may continue during and after the 4-week course with treatment of Enfiera injection drug.

Safety and not established for subsequent infusion.

Enfiera 100 mg

ADMINISTRTION :

Take an amount Enfiera injection is administer and diluted to final concentration of 1 mg/ml up to 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Gently Invert the bag and mix the solution. Discard unused drug left in vial.

OVERDOSAGE:

If over dose occurs seek immediately to the emergency department or poison control help line. Please consult the doctor for further clarification.

PHARMACOKINETICS

Absorption:

Not available

Distribution:

volume of distribution is 3.1 L There is no human plasma level

Metabolism:

Enfiera 100mg metabolized by human antimurine antibody production.

Elimination :

not available The drug elimination of half-life of NHL is 22 days and for RA is 18.0 days, GPA and microscopic polyangiitis is 23 days.

MECHANISM OF ACTION

Enfiera 100mg is a type of class called as monoclonal antibody. A new type of "targeted" cancer treatment and an integral part of the body's immune system. Naturally the body fused to antibodies in along with an antigen which has entered the body and attack the antigen for destruction by the immune system.

Monoclonal antibiotics which only targeted by an essential cell only, they may cause less toxicity to healthy cell and it is prescribed treatment given only for cancers in which antigens (and the respective antibodies) have been already identified.

Enfiera injection works by linking to the CD20 antigen on normal and malignant B-cells. Hence natural immune security of body are initiated to attach and kill the marked B-cells. Young cells (stem cells) in the bone marrow which will develop into the various cell types and do not have the CD20 antigen. After treatment CD20 antigen allows healthy B-cells to multiply.

PRECAUTIONS :

Allergic condition against Enfiera 100mg or any other medication inform your doctor. Information about past medical history used which include in prescription, non-prescription, vitamins &supplements, nutritional products just inform the doctor.

While using Enfiera 100mg do not take any vaccination or immunization without taking advice from doctors.

Avoid use of Enfiera 100mg if you are pregnant. It will harm the baby unborn, while using Enfiera 100mguse correct birth control to prevent pregnancy and for at least 2 weeks after your treatment ends. Enfiera 100mgmay affect the ability to have children in women. Inform your doctor if you planning to pregnant.

It is unknown whether Enfiera 100mg passes into breast milk, avoid breast-feed while on Enfiera 100mgtreatment.

STORAGE

Store the drug at 2℃ – 3℃

Keep away from the childerns

Use the drug before expiry date

Protected from direct sunlight and Do not freeze or shake.

Discard the unused drug by asking the advice from doctor or pharmacist.

DRUG INTERACTION

Enfiera 100mg drug interaction has limited data is available at present.
Interaction with fludarabine or cyclophosphamide have no effects in pharmacokinetics in CLL patients. Enfiera combination with methotrexate had no effects in pharmacokinetics.

CONTRAINDICATION

Hypersensitivity or murine proteins.
Active severe infections in rheumatoid arthritis
Uncontrolled cardiac disease.

MISSED DOSE

If a dose missed then have the drug soon you remembered, if next dose time reach then leave the missed dose and follow the normal schedule.
Do not have 2 doses at a same time. Please consult with doctor for further details.

SIDE EFFECTS

Common effects: fever and chills (flu lik symptoms)
Less common side effects: Weakness; nausea ; headache; cough ; dyspnea ; pharyngitis.

 

for more information please click this link below - Enfiera 100 mg , Enfiera 100 mg Injection

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals

PIRFENEX (PERFENIDONE) applepharmaceutical

PIRFENEX

DESCRIPCIÓN

Tablet Pirfenex es un fármaco eficaz, pero causa algunas afecciones potencialmente mortales. pirfenex precio Causa una estructura cromosómica anormal en pacientes que reciben Tablet Pirfenex; exposición

a la luz en pruebas de genotoxicidad. El paciente debe tener conocimiento sobre el potencial del medicamento Pirfenex

que causa carcinogénesis en la piel expuesta a la luz. La tableta Pirfenex se debe prescribir bajo la supervisión de

médico que está familiarizado con la terapia idiopática de fibrosis pulmonar. Tablet Pirfenex es un agente antifibrótico

involucrado en el tratamiento de la fibrosis pulmonar idiopática (enfermedad pulmonar).




INDICACIÓN




La tableta Pirfenex se usa principalmente en la condición de fibrosis pulmonar idiopática (FPI).




FARMACOLÓGICO




Pirfenex, el mecanismo de acción de la droga no está completamente establecido. Tablet Pirfenex es un

eficaz agente antifibrótico y antiinflamatorio. La actividad antifibrótica de Pirfenex se toma principalmente

en consideración. Pirfenex, se lleva a cabo la cantidad de terapia basada en células. Conduce a reducir la proliferación de fibroblastos,

prohíbe la producción acelerada de colágeno TGF-β y disminuye la síntesis de mediadores fibrogénicos como TGF-β (transformante

factor de crecimiento). Pirfenex tiene actividad para reducir la producción de mediadores inflamatorios como TNF-α (factor de necrosis tumoral) e IL-1β (interleucina 1 beta).







DOSIFICACIÓN




La dosis recomendada de tableta Pirfenex en adolescentes es de 200 mg durante tres veces al día (TID), 600 mg / día.

Dependiendo de la gravedad de la afección (IPF), la dosis puede ajustarse hasta 1800 mg / día. Dosis de la

tableta Pirfenex dependiendo del síntoma. Inicialmente, el paciente comienza con 200 mg de TID, después de 2 semanas, la dosis puede aumentar gradualmente a 600 mg a la vez (1800 mg / día).







Ajuste de dosis y otras consideraciones para un uso seguro:







Eventos gastrointestinales:

MABTAS RA - 500MG Applepharmaceutical

MABTAS RA - 500MG  Applepharmaceutical

DESCRIPTION :

Mabtas RA 500mg  is an anticancer medicine which prevents the growth and spread of cancer cells in the body.
Mabtas RA 500mg will help to prevent the Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with another anticancer drug like methotrexate is used for rheumatoid arthritis symptoms in adult treatment.
Mabtas RA 500mg inj  with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.




INDICATIONS :

Mabtas RA 500mg inj  and hyaluronidase human injection are given alone or combination with otherdrugs to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC).
Mabtas RA 500mg inj  injection combination with methotrexate (Otrexup, Rasuvo, Xatmep, others) is also indicated for the treatment rheumatoid arthritis symptoms in adults that have been already treated with a some type of regimen knowns as tumor necrosis factor (TNF) inhibitor. Mabtas RA 500mg is a type in a classification of drugs called monoclonal antibodies.
Mabtas RA 500mg is used to killing cancer cells to treat NHL , CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by inhibiting the activity of the immune system parts that can injury the joints, veins, and other blood vessels and cause organs (heart and lungs) damage.



DOSAGE :
Mabtas RA injection is usually used to administrate only via intravenous infusion not by IV push or bolus.
Before Each Infusion the Drug Is Premediate :
First infusion:
Starting treatment rate of 50 mg/hr. is administer, in not showing infusion toxicity, rate raised up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.

Successive infusion:  

initial at rate of 100 mg/hr., in not showing infusion toxicity, rate raised up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
While combination with CHOP chemotherapy the injection Mabtas RA has not been given. Hence Premedication with corticosteroids must be considered.

Low grade or follicular non-Hodgkin’s lymphoma:

The drug Dose is 375 mg/m2 as an IV infusion.

Once weeks for 4 or 8 doses administrated for Relapsed treatment

Once weekly for 4 doses administrated for Retreatment for relapsed.

Mabtas RA 500mg inj

Previously untreated:

administer on day 1 of each cycle of chemotherapy, up to 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Mabtas RA 500mg in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent.

Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non – progression (following CVP chemotherapy completion 6 – 8 cycles):

On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse Large B- cell NHL

Chronic Lymphocytic Leukemia :

Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.

Component of Zevalin for treatment of NHL:

The dose 250 mg/m2 of Mabtas RA injection within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-) Zevalin.

7–9 days before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin.




Rheumatoid Arthritis:

When combination of Mabtas RA injection with methotrexate is administrated.

Mabtas RAinjection given as two doses of 100mg IV infusion 2 weeks separated.

When glucocorticoids administered as methylprednisolone 100mg IV

Subsequent course based on clinical evaluation must administer every 24 weeks, but not early than every 16 weeks.

Granulomatosis Polyangiitis And Microscopic Polyangiitis :

Mabtas RA injection administer Dose of 375 mg/m2 IV infusion weekly once for 4 weeks.

When Glucocorticoids given with methylprednisolone by dose of 1000 mg IV/ day for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vacuities This drug should initiate within 14 days before or with the starting of Mabtas RAinjection and may continue during and after the 4-week course with treatment of Mabtas RAinjection drug.

Safety and not established for subsequent infusion.

ADMINISTRTION :

Take an amount Mabtas RAinjection is administer and diluted to final concentration of 1 mg/ml up to 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Gently Invert the bag and mix the solution. Discard unused drug left in vial.

OVERDOSAGE:

If over dose occurs seek immediately to the emergency department or poison control help line.

please consult the doctor for further clarification.







DRUG INTERACTION

Mabtas RA 500mg  drug interaction has limited data is available at present.

Interaction with fludarabine or cyclophosphamide have no effects in pharmacokinetics in CLL patients.

Mabtas RA combination with methotrexate had no effects in pharmacokinetics.




CONTRAINDICATION

Hypersensitivity or murine proteins.

Active severe infections in rheumatoid arthritis

Uncontrolled cardiac disease.




MISSED DOSE

If a dose missed then have the drug soon you remembered, if next dose time reach then leave the missed dose and follow the normal schedule.

Do not have 2 doses at a same time. Please consult with doctor for further details.




SIDE EFFECTS

Common effects: fever and chills (flu lik symptoms)

Less common side effects: Weakness; nausea ; headache; cough ; dyspnea ; pharyngitis.

for more information : Mabtas RA 500mg,Mabtas RA 500mg inj

Phone :+91-9987711567Email :

applepharmaceutical@gmail.com

Email :

info@myapplepharma.com

0091-9987711567

VIVITRA - 150MG Applepharmaceutical

DESCRIPTION :

vivitra 150 mg is a group of medicines which belongs to antineoplastic medication. vivitra 150 mg injection is a chemotherapy drug. It is recommended that Vivitra 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.



USES :

The injection vivitra 150 mg is used alone or combined with other medicine for the treatment in patients who suffer . vivitra 150 mg injection from metastatic breast cancer.

The drug also indicated with a combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.



WORK AS

vivitra 150 mg Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.

Vivitra acts by adhering itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Vivitra can slow or inhibit the growth of breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.



DOSAGE :

The injection vivitra 150 mg should not mix with other drugs and do not administer as an intravenous push or bolus.

Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine

Adjuvant treatment, breast cancer:

The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:

During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:

Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV (intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Vivitra dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.

The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens: For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg

Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.

Adjuvant treatment stretching beyond one year is not recommended.

Metastatic Treatment, Breast Cancer:

Vivitra administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.

Metastatic Gastric Cancer:

Vivitra administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.



PRECAUTION :

Embryo fetal damage

Vivitra 150mg is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment




Cardiomyopathy

Patient getting Vivitra 150mg injection have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinuing.

vivitra 150 mg injection

Pulmonary toxicity

Some serious fatal cases of pulmonary toxicity occur during Vivitra 150mg treatment.




Infusion reactions

During Vivitra 150mg treatment some life-threatening infusion reactions are produced.

In serious infusion reactions, Stop the Vivitra 150mg treatment permanently.

Patient should be treated with premedication before starting the infusion to overcome the such problem, During Vivitra 150mg treatment. Use with Caution.




Therapy induced neutropenia

Higher incidence of neutropenia occurs during Vivitra 150mg treatment.




DRUG SUMMARY
Probably no contraindicated occurs.
The patients are contraindicated to the component present in the Vivitra 150mg, Hence Hypersensitivity reactions are occurring.


STORAGE
Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Vivitra 150mg diluted bag at 2℃ to 8℃ for 24 hours.


MISSED DOSE
The drug Missing vivitra 150 mg injection doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.


SIDE EFFECTS :
Common side effects:
Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain


Serious side effects:
Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals

ZELGOR - 500MG (Applepharmaceutical)

ZELGOR - 500MG  (Applepharmaceutical)

Abiraterone is sold under brand name Zelgor 500mg ,( zelgor 500mg price in india ) belongs to type of anti-cancer medication that will act by a decline the androgen production in the body.
Androgen is a male hormone that can maintain the tumor cell in prostate glands.
This drug is given by co-administration with prednisolone, a steroid which reduces the liability of side effects produced by Abiraterone.

DOSAGE

The prescribed dose of  zelgor 500mg price in indiais initial as 4 tablets given orally once daily.
The drug Zelgor administrated combination with 5mg prednisolone twice daily in empty stomach.
• Zelgor 500mg Tablets given on an empty stomach.
• Food should not be taken for at least 2 hours before and at least 1 hour after the dose of Zelgor Tablets is taken. • Swallowed whole with water. • Chew the tablets or Do not crush

Zelgor 500mg

MECHANISM OF ACTION :

Androgens are balance the production of malignant in prostate.

Zelgor 500mg belongs to anti androgen drugs, that causes to suppress the enzyme 17α-hydroxylase C 17, 20-lyase (CYP17), it is involving in androgen conglomerate.

Reduce the serum testosterone level.

Declined the tumor cell occurred.

PHARMACOKINETICS

Absorption:

Time to maximum plasma concentration of Zelgor 500mg tablet takes 12 hours.

Distribution:

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism:

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Excretion:

The drug mainly excreted in 88% feces and 5% in urine

Half-life of tablet Zelgor 500mg is 12 ± 5 hours.

for more information please click this link below -Zelgor 500mg , zelgor 500mg price in india .

HERMAB - 150MG (Applepharmaceutical)

HERMAB - 150MG (Applepharmaceutical)

DESCRIPTION :

hermab 150mg  is a group of medicines which belongs to anti neoplastic medication.Hermab 150 mg injection is a chemotherapy drug. It is recommended that hermab 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.

USES
The injection hermab 150mg  is used alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.
The drug also indicated with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.

WORK AS

Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.

hermab 150mg  acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals,hermab 150mg  can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting hermab 150mg  receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.

DOSAGE :

The injection Hermab should not mix with other drugs and do not administer as an intravenous push or bolus.
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine
Adjuvant treatment, breast cancer:
The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:
During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:
Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV(intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Hermab dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.
The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer:
Hermab administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer:
Hermab administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.

PRECAUTION :

DRUG INTERACTION

In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals.
Do not take anthracycline treatment for 7 months after stopping the Hermab 150mg treatment.
Hermab 150mg interaction with anthracycline after ending of Hermab 150mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.

CONTRAINDICATION

Probably no contraindicated occurs. The patients are contraindicated to the component present in the Hermab 150mg, Hence Hypersensitivity reactions are occurring.

STORAGE

Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Hermab 150mg diluted bag at 2℃ to 8℃ for 24 hours.

MISSED DOSE :

The drug Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.

hermab 150mg

SIDE EFFECTS :

Common side effects:
Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain

Serious side effects:

Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing


for more information please click this link below - Hermab 150mg , Hermab 150 mg injection

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals